Compile Data Set for Download or QSAR
Report error Found 40 of affinity data for UniProtKB/TrEMBL: P0AD63
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 42 | US9120808, Example 41)
Affinity DataIC50: 0.400nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178167(US9120808, Example 46 | US9120808, Example 47)
Affinity DataIC50: 0.5nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178215(US9120808, Example 58)
Affinity DataIC50: 0.600nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178163(US9120808, Example 42 | US9120808, Example 41)
Affinity DataIC50: 0.800nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178170(US9120808, Example 49)
Affinity DataIC50: 2.60nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178171(US9120808, Example 50)
Affinity DataIC50: 3.20nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178167(US9120808, Example 46 | US9120808, Example 47)
Affinity DataIC50: 3.40nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178169(US9120808, Example 48)
Affinity DataIC50: 4.20nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178165(US9120808, Mixture of Example 43 and Example 44)
Affinity DataIC50: 4.30nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178198(US9120808, Example 18)
Affinity DataIC50: 13.9nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178214(US9120808, Example 57)
Affinity DataIC50: 22.6nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50021959(antibiotic MM 14151 | CHEMBL777 | MM 14151 | clavu...)
Affinity DataIC50: 30.3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178201(US9120808, Example 26)
Affinity DataIC50: 36.3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM60600(US9120808, Example 13)
Affinity DataIC50: 47.7nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178203(US9120808, Example 34)
Affinity DataIC50: 50.3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178200(US9120808, Example 24)
Affinity DataIC50: 62.2nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178196(US9120808, Example 16)
Affinity DataIC50: 80.5nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178204(US9120808, Example 37)
Affinity DataIC50: 141nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178188(US9120808, Example 7)
Affinity DataIC50: 217nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178210(US9120808, Example 53)
Affinity DataIC50: 219nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50053173((2S,3S,5R)-3-Methyl-4,4,7-trioxo-3-[1,2,3]triazol-...)
Affinity DataIC50: 222nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178211(US9120808, Example 54)
Affinity DataIC50: 295nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178202(US9120808, Example 32)
Affinity DataIC50: 339nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178209(US9120808, Example 51)
Affinity DataIC50: 436nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178199(US9120808, Example 19)
Affinity DataIC50: 617nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178145(US9120808, Example 28 | US9120808, Example 27)
Affinity DataIC50: 624nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178153(US9120808, Example 36 | US9120808, Example 35)
Affinity DataIC50: 642nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178189(US9120808, Example 9 | US9120808, Example 8)
Affinity DataIC50: 1.04E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178205(US9120808, Example 38a | US9120808, Example 38)
Affinity DataIC50: 1.71E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178153(US9120808, Example 36 | US9120808, Example 35)
Affinity DataIC50: 2.31E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178180(US9120808, Example 59)
Affinity DataIC50: 3.60E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM50021954(UNASYN | 3,3-Dimethyl-4,4,7-trioxo-4lambda*6*-thia...)
Affinity DataIC50: 3.92E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 3.95E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178194(US9120808, Example 15 | US9120808, Example 14)
Affinity DataIC50: 4.43E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178207(US9120808, Example 39)
Affinity DataIC50: 5.61E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178205(US9120808, Example 38a | US9120808, Example 38)
Affinity DataIC50: 6.81E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178186(US9120808, Example 6 | US9120808, Example 5)
Affinity DataIC50: 7.14E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178145(US9120808, Example 28 | US9120808, Example 27)
Affinity DataIC50: 9.32E+3nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178197(US9120808, Example 17)
Affinity DataIC50: 2.13E+4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent

TargetBeta-lactamase SHV-1(Escherichia coli)
Nabriva Therapeutics

US Patent
LigandPNGBDBM178194(US9120808, Example 15 | US9120808, Example 14)
Affinity DataIC50: 8.51E+4nMpH: 7.0 T: 2°CAssay Description:The inhibitory concentrations (IC50, [uM]) of the beta -lactamase inhibitors against purified TEM-1, SHV-1 and AmpC beta -lactamases are assessed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2016
Entry Details
Go to US Patent